Evidence map›Paper›PMID 20523729›Full record

ArticlePloS one2010

High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China.

Hong Shang, Ping Zhong, Jing Liu, Xiaoxu Han, Di Dai, Min Zhang, Ke Zhao, Rongzhen Xu, Xiao-Fang Yu

Abstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. High Prevalence of Hepatitis C virus Among Injection Drug Users in Zhenjiang, Jiangsu, China.Indian journal of virology : an official organ of Indian Virological Society · 2011
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hong ShangKey Laboratory of AIDS Immunology of Ministry of Health, No 1 Hospital of China Medical University, Shenyang, Liaoning, China. hongshang100@hotmail.com
Ping Zhong
Jing Liu
Xiaoxu Han
Di Dai
Min Zhang
Ke Zhao
Rongzhen Xu
Xiao-Fang Yu

Funding

Implications of HIV in Low HCV Clearance in Chinese IDUsR01DA016540 · NIDA · JOHNS HOPKINS UNIVERSITY · PI YU, XIAO-FANG · 2003 to 2007
$3.1M
NIDA NIH HHS DA016540NIDA NIH HHS R01 DA016540
6 · The paper itself

Abstract

backgroundCo-infection with HIV-1 and HCV is a significant global public health problem and a major consideration for anti-HIV-1 treatment. HCV infection among HIV-1 positive people who are eligible for the newly launched nationwide anti-HIV-1 treatment program in China has not been well characterized. METHODOLOGY: A nationwide survey of HIV-1 positive injection drug uses (IDU), former paid blood donors (FBD), and sexually transmitted cases from multiple provinces including the four most affected provinces in China was conducted. HCV prevalence and genetic diversity were determined. We found that IDU and FBD have extremely high rates of HCV infection (97% and 93%, respectively). Surprisingly, people who acquired HIV-1 through sexual contact also had a higher rate of HCV infection (20%) than the general population. HIV-1 subtype and HCV genotypes were amazingly similar among FBD from multiple provinces stretching from Central to Northeast China. However, although patterns of overland trafficking of heroin and distinct HIV-1 subtypes could be detected among IDU, HCV genotypes of IDU were more diverse and exhibited significant regional differences.

conclusionEmerging HIV-1 and HCV co-infection and possible sexual transmission of HCV in China require urgent prevention measures and should be taken into consideration in the nationwide antiretroviral treatment program.

Indexed as

Genetic VariationChinaGenotypeGeographyHepacivirusHepatitis CHIV-1HIV InfectionsHIV SeropositivityHumansPhylogenyPrevalenceRisk FactorsSubstance Abuse, Intravenous

Identifiers

PMID20523729
PMCPMC2877711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.